Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Sirnaomics Licenses Polypeptide Nanoparticle Technology for Its siRNA Therapeutic Product Development

Abstract:
Sirnaomics, Inc. announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School. The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of Histidine-Lysine polymer (HKP) for siRNA therapeutics in the areas of wound healing and ocular diseases (U.S. patent application 60/173,576 filed December 29, 1999).

Sirnaomics Licenses Polypeptide Nanoparticle Technology for Its siRNA Therapeutic Product Development

Gaithersburg, MD | Posted on January 13th, 2010

Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases.

RNAi plays a multifunctional role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and, in its best-studied mode of action, reducing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions, investments and mergers have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutics development. Consequently, there are more than a dozen clinical trials currently ongoing for various therapeutic applications of RNAi.

Sirnaomics' mission is to advance RNAi technology for rapid development of novel siRNA therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design is reflecting the unique advantage of siRNA-based active pharmaceutical ingredient (API) in knocking down multiple disease-causing genes in the same treatment. Through in-house efforts and collaborations, Sirnaomics is developing nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles (1st), ligand-directed nanoparticles (2nd), and infrared-activated nanoparticles (3rd), for various types of therapeutic applications. The "Snano" series of the company's siRNA delivery technology are representing the 1st generation and will be complemented by the addition of the licensed HKP technology.

"Licensing the Histidine-Lysine polymer nanoparticle technology is rooted in our long time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle. The two year collaboration between Dr. Mixson and Sirnaomics, supported by a Maryland Industrial Partnerships (MIPS) grant, facilitated progress of our scarless wound healing program and resulted in the discovery and development of STP705 (Cutasil®)," said the President and CEO of the company, Dr. Patrick Y. Lu. "The collaboration and licensing agreement have provided an important foundation for Sirnaomics' technology and product development. We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology."

"STP705 is a topically applied formulation for delivery of the siRNAs to the wound site and it has demonstrated accelerated wound repair yet with reduced scar formation in both murine and swine excisional wound models." explained Dr. David Evans, the company's vice president for discovery research. "The remarkable therapeutic benefits of STP705 in these models have clearly demonstrated the power of HKP for in vivo siRNA delivery and, based on our extensive data set we are actively seeking partnerships to drive STP705 to the market". The exciting experimental results will be reported during the upcoming Keystone Symposia "RNA Silencing: Mechanism, Biology and Application" on January 14-19, 2010.

####

About Sirnaomics
Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established in 2007 by a group of leading scientists in the field of RNAi technology, the company is pursuing the mission of advancing RNAi technology with novel targeted therapeutics development. In 2008, the company established its subsidiary in Suzhou, China to expand its R&D capacity and potential market. Members of the senior management team bring over 60 years of combined experience in the biopharmaceutical, financial and business management industries. Supported with funding from founders, angel investors, government grants and China-Singapore VC, Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of interest include wound healing, pandemic flu (H5N1/H1N1), ocular diseases, oncology, spinal cord injury and transplantation.

For more information, please click here

Contacts:
George J. Ji
Sirnaomics, Inc.
401 Professional Drive, Suite 130
Gaithersburg, MD 20879, USA
301-740-1730 Phone
301-740-1731 FAX

Copyright © Sirnaomics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Patents/IP/Tech Transfer/Licensing

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

Nanobiotechnology

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Seeing is bead-lieving: Rice University scientists create model 'bead-spring' chains with tunable properties July 28th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE